Over the past decades, experimental studies and clinical trials have demonstrated that valsartan seceratively blocked Ang II type 1 receptor (AT1R) and thus, it was widely used in treatment of Ang II-involved cardiovascular disorders, such as hypertension, endothelial dysfunction [12] and abdominal aortic aneurysm [13]. Here, AGTR1 is linked to cardiovascular disorder.